Skip to content

Clinical trials

Phase 1 Adenocarcinoma of Lung trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Adenocarcinoma of Lung Phase: Phase 1 Clear all

54 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20002
20011
20022
20031
20045
20051
20062
20071
20081
20092
20121
20132
20143
20152
20162
20172
20191
20205
20211
20232
20243
20255
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed25
Terminated10
Recruiting5
Not yet recruiting4
Unknown status4
Active, not recruiting3
Withdrawn3

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Roswell Park Cancer Institute5
Memorial Sloan Kettering Cancer Center3
National Cancer Institute (NCI)3
Bayer2
Ikena Oncology2
Jonsson Comprehensive Cancer Center2
Novartis Pharmaceuticals2
University of Pennsylvania2
University of Texas Southwestern Medical Center2
University of Washington2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Adenocarcinoma of Lung54
Carcinoma, Non-Small-Cell Lung33
Lung Neoplasms26
Adenocarcinoma, Bronchiolo-Alveolar11
Neoplasms9
Breast Neoplasms8
Colorectal Neoplasms7
Ovarian Neoplasms7
Pancreatic Neoplasms7
Triple Negative Breast Neoplasms6

Trials

Showing 76 to 54 of 54. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.